We also developed a novel HIF-2α targeted inhibitor YQ-0629, which synergizes with PTX to suppress tumor growth in vitro and in vivo and represents a promising small molecule compound for breast cancer targeted therapy. This evidence concerns the gene EPAS1 and breast carcinoma.